VIP152 for Chronic Lymphocytic Leukemia

"Data collected thus far suggests that VIP152 is relatively safe, subsequently earning it a score of 1. As this is only the first phase in testing its efficacy and safety, additional research needs to be conducted."

"Currently, 4 clinical trial sites are enrolling patients for this medical study. Locations include Seattle, Columbus and Cincinnati as well as one other location. To reduce the need to travel extensively, it is best to select a site close by when applying."

"This trial necessitates the enrollment of 54 suitable patients. Subjects can be recruited from a variety of locations, such as Fred Hutchinson Cancer Research Center in Seattle and The Ohio State University located in Columbus."

"Per the trial sponsor, Vincerx Pharma Inc., Maximum tolerated dose will be monitored over a three-year period to determine the primary outcome. Secondary outcomes such as Overall Survival Rate (Time Between First Dose Date and Date of Death), Progression Free Survival (Number of Participants Without Disease Progression per iwCLL guidelines for CLL & Lugano Classification for NHL) and Tumor Response (Tumor response evaluation based on the response criteria as applicable for CLL and Richter Syndrome) will also be evaluated."

"Affirmative. According to clinicaltrials.gov, this trial is actively seeking volunteers; it was initially posted on December 16th 2021 and recently updated on August 3rd 2022. To meet the requirements of the study, 54 subjects need to be recruited from 4 medical locations."